文献速递甲状腺与浅表US

C-TIRADS、ACR-TIRADS与EU-TIRADS用于甲状腺结节诊断与管理的比较研究

Comparative Study of C-TIRADS, ACR-TIRADS, and EU-TIRADS for Diagnosis and Management of Thyroid Nodules.
PubMed 文献 · Acad Radiol · 2023-05-23

该研究回顾性纳入2013年1月至2019年11月间3013例患者的3438个甲状腺结节(≥10 mm),比较C-TIRADS、ACR-TIRADS与EU-TIRADS鉴别良恶性及指导细针穿刺活检的效能。C-TIRADS的AUROC为0.857、AUPRC为0.605,均高于ACR-TIRADS(0.844、0.567)和EU-TIRADS(0.802、0.455);C-TIRADS不必要的FNAB率最低(21.2%),对ACR-TIRADS和EU-TIRADS的FNAB推荐净重分类改善分别为19.0%和25.5%(P均<0.001)。作者认为C-TIRADS可能是临床可用的甲状腺结节管理工具,但需在其他地区进行充分验证。

要点

  • C-TIRADS的AUROC 0.857高于ACR-TIRADS的0.844和EU-TIRADS的0.802。
  • C-TIRADS不必要的FNAB率21.2%,低于ACR-TIRADS的41.7%和EU-TIRADS的58.3%。
  • C-TIRADS敏感度85.3%低于ACR-TIRADS的89.1%、高于EU-TIRADS的78.4%。

核心结论

  • C-TIRADS可能是一个临床可用的甲状腺结节管理工具,但需在其他地区进行充分验证。

研究设计与样本

  • 回顾性研究,纳入3013例患者的3438个甲状腺结节(≥10 mm),诊断时间为2013年1月至2019年11月,平均年龄47.1岁±12.9;依据三种TIRADS的词典评估超声特征并分类,比较AUROC、AUPRC、敏感度、特异度、净重分类改善及不必要的FNAB率。

关键影像表现/征象

  • 3438个甲状腺结节中707个(20.6%)为恶性。
  • C-TIRADS的AUROC为0.857、AUPRC为0.605,高于ACR-TIRADS(AUROC 0.844、AUPRC 0.567)和EU-TIRADS(AUROC 0.802、AUPRC 0.455)。
  • C-TIRADS敏感度85.3%低于ACR-TIRADS的89.1%、高于EU-TIRADS的78.4%。
  • C-TIRADS特异度76.9%与EU-TIRADS的78.9%相似、高于ACR-TIRADS的69.5%。
  • C-TIRADS不必要的FNAB率21.2%最低,ACR-TIRADS为41.7%、EU-TIRADS为58.3%。

诊断标准与关键数值

  • C-TIRADS的AUROC 0.857、AUPRC 0.605、敏感度85.3%、特异度76.9%,不必要FNAB率21.2%。
  • ACR-TIRADS的AUROC 0.844、AUPRC 0.567、敏感度89.1%、特异度69.5%,不必要FNAB率41.7%。
  • EU-TIRADS的AUROC 0.802、AUPRC 0.455、敏感度78.4%、特异度78.9%,不必要FNAB率58.3%。
  • C-TIRADS推荐FNAB较ACR-TIRADS的NRI为19.0%(P<0.001),较EU-TIRADS的NRI为25.5%(P<0.001)。

临床应用与阅片要点

  • 作者认为C-TIRADS可能是临床可用的甲状腺结节管理工具。
  • 作者指出C-TIRADS需在其他地区进行充分验证。

局限性

  • 原文结论指出C-TIRADS需在其他地区进行充分验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Chinese Thyroid Imaging Reporting and Data Systems (C-TIRADS) was developed to provide a more simplified tool for stratifying thyroid nodules. Here we aimed to validate the efficacy of C-TIRADS in distinguishing benign from malignant and in guiding fine-needle aspiration biopsies in comparison with the American College of Radiology TIRADS (ACR-TIRADS) and European TIRADS (EU-TIRADS).

MATERIALS AND METHODS: This study retrospectively included 3438 thyroid nodules (≥10 mm) in 3013 patients (mean age, 47.1 years ± 12.9) diagnosed between January 2013 and November 2019. Ultrasound features of the nodules were evaluated and categorized according to the lexicons of the three TIRADS. We compared these TIRADS by using the area under the receiver operating characteristic curve (AUROC), the area under the precision-recall curve (AUPRC), sensitivity, specificity, net reclassification improvement (NRI), and unnecessary fine-needle aspiration biopsy (FNAB) rate.

RESULTS: Of the 3438 thyroid nodules, 707 (20.6%) were malignant. C-TIRADS showed higher discrimination performance (AUROC, 0.857; AUPRC, 0.605) than ACR-TIRADS (AUROC, 0.844; AUPRC, 0.567) and EU-TIRADS (AUROC, 0.802; AUPRC, 0.455). The sensitivity of C-TIRADS (85.3%) was lower than that of ACR-TIRADS (89.1%) but higher than that of EU-TIRADS (78.4%). The specificity of C-TIRADS (76.9%) was similar to that of EU-TIRADS (78.9%) and higher than that of ACR-TIRADS (69.5%). The unnecessary FNAB rate was lowest with C-TIRADS (21.2%), followed by ACR-TIRADS (41.7%) and EU-TIRADS (58.3%). C-TIRADS obtained significant NRI for recommending FNAB over ACR-TIRADS (19.0%, P < 0.001) and EU-TIRADS (25.5%, P < 0.001).

CONCLUSION: C-TIRADS may be a clinically applicable tool to manage thyroid nodules, which warrants thorough tests in other geographic settings.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Jin, Pei, Shen, et al. Comparative Study of C-TIRADS, ACR-TIRADS, and EU-TIRADS for Diagnosis and Management of Thyroid Nodules. Acad Radiol. 2023. PMID: 37230821. doi:10.1016/j.acra.2023.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。